Bajaj Healthcare Limited

BSE: BAJAJHCARE539872ISIN INE411U01027

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹308.45+2.30 (+0.75%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹480.10
52W low: ₹272.45
Off 52W high: -35.75%
1M return: -3.32%
3M return: -7.37%
6M return: -7.98%
1Y return: -33.60%
20D avg volume: 11,813
50 DMA: ₹326.09
200 DMA: ₹328.27

Key ratios Standalone

Market cap: ₹1,038 Cr
Current price: ₹308.45
52W high / low: ₹480.10 / ₹272.45
Face value: ₹5.00
P/E: 50.40
P/B: 2.33
EPS (TTM): ₹6.12
Book value / share: ₹132.38
ROE: 4.62%
ROCE: 8.50%
Operating margin: 18.25%
Net margin: 8.01%
Debt / equity: 0.44
Net debt: ₹196.23 Cr
Interest cover: 2.30
Dividend yield: 0.49%
Dividend / share (TTM): ₹1.50
Payout: 24.51%
Cash conversion cycle: 199.8 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	175.90	165.63	153.06	161.22	147.91	148.84	154.47	122.79	133.09	132.25	133.90	108.57
	0.89	0.81	2.96	1.65	1.65	0.88	13.57	2.37	2.61	0.85	6.45	0.80
	176.79	166.44	156.01	162.87	149.57	149.71	168.04	125.17	135.70	133.10	140.35	109.37
	158.32	149.99	143.58	143.63	133.61	135.19	156.32	113.51	123.25	122.92	131.17	103.05
	98.41	91.59	92.10	69.41	74.81	69.88	100.49	72.67	55.03	78.91	50.63	86.65
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	19.11	17.47	16.30	15.59	16.51	14.36	15.71	14.65	13.99	12.71	10.62	11.65
	5.98	6.09	5.57	5.88	5.56	5.23	6.08	5.51	7.88	8.44	6.01	6.65
	7.65	7.01	7.63	7.20	7.08	5.64	7.53	6.85	6.81	6.73	7.30	7.35
	34.21	33.31	32.57	34.26	30.86	29.38	33.04	25.59	28.59	29.45	23.55	26.10
	18.48	16.46	12.44	19.25	15.96	14.53	11.72	11.65	12.45	10.18	9.18	6.33
	0.00	0.00	-33.25	0.00	0.00	0.00	0.00	—	—	—	-44.33	—
	18.48	16.46	-20.81	19.25	15.96	14.53	11.72	11.65	12.45	10.18	-35.15	6.33
	4.10	2.57	1.40	3.14	3.51	2.35	0.13	3.31	4.11	2.16	3.15	0.80
	14.09	13.70	-22.85	15.67	11.11	11.83	11.18	11.72	9.46	7.13	-29.92	-2.20
	4.27	4.13	-7.16	5.10	3.95	3.85	3.67	4.66	2.96	2.91	-11.59	2.00
Key metrics
	32.11	29.56	-7.61	32.33	28.60	25.40	25.33	24.01	27.14	25.35	-21.84	20.33
	18.30%	17.80%	-5.00%	20.10%	19.30%	17.10%	16.40%	19.60%	20.40%	19.20%	-16.30%	18.70%
	8.00%	8.30%	-14.90%	9.70%	7.50%	7.90%	7.20%	9.50%	7.10%	5.40%	-22.30%	-2.00%
	3.70%	—	-2.50%	—	3.80%	—	3.20%	—	—	—	—	—
	18.90%	11.30%	-0.90%	31.30%	11.10%	12.50%	15.40%	13.10%	—	—	—	—
	26.80%	15.80%	-304.40%	33.70%	17.40%	65.90%	137.40%	632.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	655.81	611.03	542.60	473.42	673.29	679.89
	6.31	7.13	19.40	8.69	1.60	1.44
	662.11	618.17	562.01	482.10	674.89	681.33
	595.52	556.00	516.00	454.45	616.67	591.65
	351.51	306.20	307.11	264.43	520.45	499.82
	0.00	0.00	0.00	—	—	—
	68.47	62.75	57.06	43.85	47.84	41.11
	23.52	22.23	27.90	29.68	22.87	12.62
	29.49	27.55	27.92	27.62	27.36	17.64
	134.35	127.07	116.67	98.53	27.95	24.23
	66.63	62.17	46.01	27.65	58.22	89.69
	-33.25	-33.25	0.00	-44.33	—	—
	33.38	28.92	46.01	-16.68	58.22	89.69
	11.21	7.61	3.08	2.35	15.19	18.30
	20.61	15.77	39.50	-83.79	43.02	71.39
	6.34	6.73	14.45	-5.19	15.59	25.87
Key metrics
	86.39	78.70	101.83	40.62	108.45	119.95
	13.17%	12.90%	18.80%	8.60%	16.10%	17.60%
	3.14%	2.60%	7.30%	-17.70%	6.40%	10.50%
	—	8.50%	13.20%	—	—	—
	14.25%	12.60%	14.60%	-29.70%	-1.00%	—
	-55.04%	-60.10%	147.10%	-294.80%	-39.70%	—
	—	14.73	10.08	—	—	—
	—	3.68	0.55	—	—	—
	—	0.44	0.48	—	—	—
	—	196.23	220.03	—	—	—
	—	199.8	214.0	—	—	—
Balance sheet
	—	923.22	833.05	—	—	—
	—	569.08	485.40	—	—	—
	—	37.24	2.60	—	—	—
	—	233.85	251.67	—	—	—
	—	216.01	161.89	—	—	—
	—	76.00	33.96	—	—	—
	—	247.22	236.56	—	—	—
	—	115.28	95.47	—	—	—
	—	319.56	272.27	—	—	—
	—	233.47	222.63	—	—	—
	—	185.90	157.96	—	—	—
	—	47.57	64.67	—	—	—
	—	533.00	466.16	—	—	—
Cash flow
	—	58.08	21.62	—	—	—
	—	-47.78	-14.82	—	—	—
	—	24.33	-6.38	—	—	—
	—	43.35	11.54	—	—	—

Compounded growth

Sales CAGR 3Y: -3.18%
Sales CAGR 5Y: —
Profit CAGR 3Y: -28.43%
Profit CAGR 5Y: —
Sales YoY (TTM): +14.25%
Profit YoY (TTM): -55.04%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 58.58%

Quarter	September 2026	June 2026
Promoter %	58.58%	58.59%

Holder	Type	Holding	Previous	Change
SAJANKUMAR RAMESHWARLAL BAJAJ	Promoter	36.61%	36.62%	-0.01%
ANIL CHAMPALAL JAIN	Promoter Group	6.05%	6.05%	0.00%
NAMRATA BAJAJ	Promoter Group	4.85%	4.85%	0.00%
NIHITA BAJAJ KUMAR	Promoter Group	4.81%	4.81%	0.00%
BABITA SAJANKUMAR BAJAJ	Promoter Group	4.47%	4.47%	0.00%
DEEPAK RAMANLAL JOSHI	Public	2.32%	2.32%	0.00%
HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND	Public	1.69%	1.69%	0.00%
PADMA ANIL JAIN	Promoter Group	0.90%	0.90%	0.00%
BAJAJ HEALTH AND NUTRITIONS LLP	Promoter Group	0.71%	0.71%	0.00%
BANSAL PHARMA LIMITED	Promoter Group	0.18%	0.18%	0.00%
SKR BAJAJ HUF	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Bajaj Healthcare Limited S	1,038	308.45	50.40	8.50%	+14.25% TTM	-55.04% TTM	-33.60%

Filings & corporate actions

Recent announcements

Transcript of Earnings Call for Q2H1FY2727 Oct 2026 · Company Update / Earnings Call Transcript
Intimation for Audio Recording of Earnings Call for Q2FY2719 Oct 2026 · Company Update / Analyst / Investor Meet
Intimation for newspaper publication19 Oct 2026 · Company Update / Newspaper Publication
Press Release on the financial results of the Company for the quarter ended September 30, 202617 Oct 2026 · Company Update / Press Release / Media Release
Statement of Deviation & Variation for the quarter ended September 30, 202617 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Monitoring Agency Report for the quarter ended September 30, 202617 Oct 2026 · Company Update / Monitoring Agency Report
Financial Results for the quarter ended September 30, 202617 Oct 2026 · Result / Financial Results
Outcome of the Board Meeting held on 17th October 202617 Oct 2026 · Board Meeting / Outcome of Board Meeting
Receipt of Hon''ble NCLT Order approving acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis14 Oct 2026 · Company Update / General
Earning Call Invite14 Oct 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 for the sale of a business unit of the Company12 Oct 2026 · Company Update / General
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2026 ,inter alia, to consider and approve the un-audited financial results ....9 Oct 2026 · Board Meeting / Board Meeting
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 20189 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for closure of Trading Window23 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Submission of Voting Results and Scrutinizer''s Report22 Sep 2026 · AGM/EGM / AGM
Proceedings of the 33rd Annual General Meeting of the Company held on September 21, 202621 Sep 2026 · AGM/EGM / AGM
Intimation of Record Date for the payment of Final Dividend for the financial year 2025-263 Sep 2026 · Corp. Action / Record Date
Intimation for newspaper publication- Dispatch of Notice of 33rd Annual General Meeting and Annual Report for the financial year 2025-2630 Aug 2026 · Company Update / Newspaper Publication
Intimation for Inland Letters sent to Shareholders29 Aug 2026 · AGM/EGM / AGM
Intimation for Business Responsibility and Sustainability Report for the financial year 2025-2629 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Intimation of the Annual Report for the financial year 2025-2629 Aug 2026 · Others / Reg. 34 (1) Annual Report
Intimation of 33rd Annual General Meeting and dispatch of Annual Report of the Company for the financial year 2025-2629 Aug 2026 · AGM/EGM / AGM
Intimation for Newspaper Publication with respect to 33rd Annual General Meeting of the Company26 Aug 2026 · Company Update / Newspaper Publication
Intimation of allotment of equity shares pursuant to exercise of ESOPs21 Aug 2026 · Company Update / Allotment of ESOP / ESPS
The Company has received the approval from DCGI to manufacture and market Cenobamate API and Tablets12 Aug 2026 · Company Update / General
Revision in Credit Rating6 Aug 2026 · Company Update / Credit Rating
Transcript of Earnings Call for Q1FY2727 Jul 2026 · Company Update / Earnings Call Transcript
Intimation for Newspaper Publication22 Jul 2026 · Company Update / Newspaper Publication
Intimation for Audio Recording of Earnings Call for Q1FY2721 Jul 2026 · Company Update / Analyst / Investor Meet
Intimation for Grant of Employee Stock Options under Bajaj Healthcare Limited Employee Stock Option Plan 202420 Jul 2026 · Company Update / General
Press Release for the quarter ended June 30, 202620 Jul 2026 · Company Update / Press Release / Media Release
Statement of Deviation & Variation for the quarter ended June 30, 202620 Jul 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Monitoring Agency Report for the quarter ended June 30, 202620 Jul 2026 · Company Update / Monitoring Agency Report
Continuation of directorship of Mr. Gopalakrishnan Kesavan as Non-Executive Independent Director of the Company upon attaining the age of 75 years20 Jul 2026 · Company Update / Change in Management
Financial Results for the quarter ended June 30, 202620 Jul 2026 · Result / Financial Results
Outcome of the Board Meeting held on July 20, 202620 Jul 2026 · Board Meeting / Outcome of Board Meeting
Earnings Call Invite16 Jul 2026 · Company Update / Analyst / Investor Meet
Earnings Call Invite16 Jul 2026 · Company Update / Analyst / Investor Meet
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....14 Jul 2026 · Board Meeting / Board Meeting
Compliance Certificate under Regulation 74(5) of SEBI (DP), Regulations, 2018 for the quarter ended June 30, 20268 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.5000	11 Sep 2026	14 Sep 2026	—
Final Dividend - Rs. - 1.0000	19 Sep 2025	19 Sep 2025	—
Final Dividend - Rs. - 1.0000	23 Sep 2024	—	—

Board meetings

17 Oct 2026 Board Meeting - Financial Results
20 Jul 2026 Board Meeting - Financial Results